A Double-blind Randomized Controlled Prospective Clinical Trial of Esomeprazole in the Prevention of Abdominal Pain after Gastroscopic Biopsy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000500

Enrollment

Unknown

Registered

2009-07-30

Start date

2009-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Gastritis

Interventions

trail group:oral Esomeprazole

control group:oral placebos

Eligibility

Sex/Gender

All

Age

20 Years to 79 Years

Inclusion criteria

Inclusion criteria: Male and female aged in 20 to 79 years old; Patients who has digestive symptoms need to perform Gastroscopy, gastroscope examination show chronic gastritis without Peptic Ulcer, upper digestive tract neoplasms, upper gastrointestinal bleeding, pyloric obstruction and gastrointestinal perforation.

Exclusion criteria

Exclusion criteria: Contradiction to undergo gastroscopy; Serious heart or pulmonary or kidney disease; pregnancy or lactation women; Patients with history of allergy of Esomeprazole and operation of gastrointestinal tract. Patients who took PPI, histamine H2 receptor blocker and gastric mucosal protective drugs in two past weeks

Design outcomes

Primary

Measure	Time frame
degrees of abdominal pain;	—

Secondary

Measure	Time frame
pH of gastric fruite;	—

Countries

China

Contacts

Public ContactLINGHU En-qiang

lheq128@sina.co+86 13501233558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026